Allopurinol/lesinurad - AstraZeneca

Drug Profile

Allopurinol/lesinurad - AstraZeneca

Alternative Names: DUZALLO; Lesinurad allopurinol FDC; Lesinurad/allopurinol; lesinurad/allopurinol 200/300 FDC; RDEA-594/allopurinol; Zurampic/Allopurinol FDC

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ardea Biosciences
  • Developer Ardea Biosciences; Grunenthal
  • Class Acetic acids; Antigouts; Cyclopropanes; Naphthalenes; Purines; Small molecules; Sulfides; Triazoles; Urologics
  • Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout

Most Recent Events

  • 06 Aug 2018 Ironwood Pharmaceuticals issues a notice of termination of the license agreement in USA
  • 29 Jun 2018 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of allopurinol/lesinurad for treatment of Gout in European Union
  • 31 Oct 2017 Launched for Gout in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top